Skip to content

Novel Technologies to Measure Vision-related Quality of Life

Feasibility Study of Novel Technologies to Measure Vision-related Quality of Life in Patients With Neurodegenerative Diseases Affecting the Optic Nerve or Retina

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07489898
Acronym
Tablet-VR
Enrollment
50
Registered
2026-03-24
Start date
2026-04-01
Completion date
2030-03-01
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inherited Optic Neuropathy, Neurodegenerative Diseases

Brief summary

Traditional ways of measuring vision, such as reading letters on an eye chart, do not fully reflect the real-life visual problems experienced by people with eye diseases. Many patients report difficulties with things like contrast, recognising faces, and identifying items whilst shopping - challenges that are not captured by standard clinical tests. As a result, it is hard to understand the true impact of these conditions on everyday life, or to measure how well new treatments are working. Some new treatments for eye diseases have shown promise, but clinical trials have often struggled to show clear benefits. This is largely because the tools used to measure vision changes in trials are not sensitive enough to detect the kinds of improvements that matter most to patients. This pilot study will explore whether novel, technology-based tests, delivered via tablets and virtual reality headsets, can better measure meaningful changes in vision and quality of life. These tools are designed to be more engaging and reflective of real-world visual tasks, such as navigating environments or detecting objects in low light. Fifty participants with neurodegenerative diseases affecting the optic nerve or retina will take part in the study. Researchers will assess how feasible and acceptable these new tools are to patients and whether the results they produce align more closely with patients' lived experiences. Ultimately, this research aims to improve how we assess vision in clinical trials, so that future treatments can be properly tested and approved based on measures that truly reflect patients' needs. If successful, it could lead to better-designed trials, more effective treatments, and improved quality of life for people living with visual impairment.

Interventions

OTHERTablet- and virtual reality headset-based test of vision-related quality of life

* Tablet-based testing of functional vision * Virtual reality headset-based testing of functional vision * Questionnaire on experience of tests * Questionnaire on experience of vision

Sponsors

Nisha Nixon
Lead SponsorOTHER
Cambridge University Hospitals NHS Foundation Trust
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults with neurodegenerative diseases affecting the optic nerve or retina who have sufficient manual dexterity to perform tablet-based and virtual reality headset-based tests. Informed consent will be received.

Exclusion criteria

* Those under the age of 18 years old * Those who do not have sufficient manual dexterity to perform the tablet-based and virtual reality headset-based tests

Design outcomes

Primary

MeasureTime frameDescription
Agreement of test performance with PROM1 dayAgreement between the tablet-based and virtual reality headset-based tests of real-world vision, with the patient's experience of their vision-related quality of life as assessed using a validated patient-reported outcome measure tool
Agreement of traditional measures of vision with PROM1 day• Secondary comparison will be made between the patient's performance on traditional measures of vision and their response on the vision-related quality of life questionnaire.

Secondary

MeasureTime frameDescription
Experience of performing tests1 day• The secondary endpoint will be the subjective experience of the tablet-based and virtual reality headset-based tests, as measured by questionnaire surveys.

Contacts

CONTACTNisha Nixon
nisha.nixon1@nhs.net01223 805000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026